Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

Autor: Teruhisa Fujii, Satoshi Higasa, Mitsuhiro Uchiba, Y. Ohashi, K. Fukutake, A. Tawa, Hideo Mugishima, Midori Shima, M. Migita, Y. Shinkoda, Akira Shirahata, K. Kawasugi, Hideji Hanabusa, Masashi Taki, Keiji Nogami, Yoshiyuki Kosaka, Hidehiko Saito, K. Sameshima, Tadashi Matsushita, K. Kawakami, Hideyuki Takedani, Junki Takamatsu, Michio Sakai

Publikováno v: Haemophilia. 23:59-66

Introduction MC710, a 1:10 protein weight ratio mixture of plasma-derived activated factor VII (FVIIa) and factor X (FX), is a novel bypassing agent for haemostasis in haemophilia patients with inhibitors. We evaluated the haemostatic efficacy and sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e604495d6605365e0cdec67ce7c0c834
https://doi.org/10.1111/hae.13050

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Autor: A. Tiede, Paul Giangrande, K. Hampton, T. Lambert, Meera Chitlur, L. Alberio, C. Negrier, H. Takedani, Michael Recht, S. Lentz, Woei Tsay, S. Dunkley, Miguel A. Escobar, T. Fujii, P. Kampmann, Christine M. Knoll, M. Shima, T. A. Andreeva, Peter G. Jönsson, Steven R. Lentz, Chris Barnes, L. Nemes, Johannes Oldenburg, K. Fukutake, B. Brand, H. Hanabusa, Elena Santagostino, M. Guerrera, E. Cockrell, Tadashi Matsushita, Jerry S. Powell, Lone Hvitfeldt Poulsen, Ralph A. Gruppo, Laszlo Nemes, J. Morales, C. Rothschild, G. Thomson, P. Chowdary, J. Felgenhauer, S. Zupancic-Salek, J. Sathar, N. Apollonsky, A. Tosetto, Roshni Kulkarni, J. Lazarchick, E. M. Mingot, S. Madoiwa, M. Misgav, V Jiménez Yuste, Z. Boda, K. Meijer, E. Zetterberg, G. K. Guron, M. Castro Ozelo, G. R. Nagasubramanian, S. Kearney, Pratima Chowdary, J. Oldenburg, C. Albayrak, Frank W.G. Leebeek, Silke Ehrenforth, Savita Rangarajan, Tatiana Andreeva, K. Kavakli, H. Eichler, L. H. Poulsen, Faraizah Abdul Karim, A. Kutlar, J. Wright, M. Trossaert, P. Kavasch, M. C. Shen, Chur Woo You, P. A. Holme, E. Santagostino, Wan Hui Ong Clausen, N. Curry, I. Sasmaz, W. Miesbach, A. Shibuya, A. Paroskie-Wheeler, E. Lowe, Clifford M Takemoto, D. Yee, F. Boehlen, S. Brown, F. W. G. Leebeek, J. Lasky, Peter William Collins, T. Sato, Robert Klamroth, K. Dunsmore

Publikováno v: Thrombosis and Haemostasis, 117(2), 252-261. Georg Thieme Verlag
Giangrande, P, Andreeva, T, Chowdary, P, Ehrenforth, S, Hanabusa, H, Leebeek, F W G, Lentz, S R, Nemes, L, Poulsen, L H, Santagostino, E, You, C W, Clausen, W H O, Jönsson, P G, Oldenburg, J & Pathfinder™2 Investigators 2017, ' Clinical evaluation of glycoPEGylated recombinant FVIII : Efficacy and safety in severe haemophilia A ', Thrombosis and Haemostasis, pp. 252-261 . https://doi.org/10.1160/TH16-06-0444

Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deca7c652b62e159aa11378000e7fe8c
https://pure.eur.nl/en/publications/5f120d71-685a-4410-9b98-59e6346a7976